ALAGILLE SYNDROME
Clinical trials for ALAGILLE SYNDROME explained in plain language.
Never miss a new study
Get alerted when new ALAGILLE SYNDROME trials appear
Sign up with your email to follow new studies for ALAGILLE SYNDROME, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Extended trial tests drug for rare childhood liver disease
Disease control Recruiting nowThis study is checking the long-term safety and effectiveness of the drug odevixibat for people with Alagille syndrome (ALGS), a rare genetic disorder that affects the liver and causes severe itching. The drug is already approved to treat itching in infants with ALGS over 12 mont…
Matched conditions: ALAGILLE SYNDROME
Phase: PHASE3 • Sponsor: Albireo, an Ipsen Company • Aim: Disease control
Last updated Apr 01, 2026 23:11 UTC
-
Tracking a rare liver disease treatment in real life
Disease control Recruiting nowThis study follows 30 patients with Alagille syndrome (ALGS), a rare genetic disease that damages the liver, as they take the medication odevixibat (Bylvay) in their daily lives. The main goal is to see how well the drug works and how safe it is over the long term. Researchers wi…
Matched conditions: ALAGILLE SYNDROME
Sponsor: Ipsen • Aim: Disease control
Last updated Mar 24, 2026 12:01 UTC
-
New study tracks Long-Term safety of liver disease medication
Disease control Recruiting nowThis study follows 100 patients with Alagille Syndrome in Europe who are already taking Livmarli for their liver disease. Researchers want to understand the long-term safety and effectiveness of this medication over time. The study monitors side effects, liver function, and wheth…
Matched conditions: ALAGILLE SYNDROME
Phase: PHASE4 • Sponsor: Mirum Pharmaceuticals, Inc. • Aim: Disease control
Last updated Mar 23, 2026 15:15 UTC